Absci Financial Statements
NASDAQ: ABSIHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Absci revenue and earnings
In fiscal 2025, Absci generated $2.8 million in revenue, down 38.2% from fiscal 2024, its first annual decline since 2024. Absci reported a net loss of $115.2 million, compared with a loss of $103.1 million a year earlier. Operating margin was -4297.0%.
Diluted earnings per share came in at -$0.84. Over the last 5 fiscal years, ABSI's revenue has grown at a -10.1% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Absci income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M | 4.78M |
| Revenue growth (YoY) | -38.24% | -20.71% | -0.50% | +20.18% | +0.04% | — |
| Operating Expenses | 123.12M | 113.42M | 121.23M | 112.50M | 80.02M | 18.08M |
| Research & Development | 81.42M | 63.86M | 48.07M | 58.91M | 44.59M | 11.45M |
| Selling, General & Admin | 35.06M | 36.17M | 37.83M | 40.55M | 28.78M | 5.50M |
| Operating Income | -120.32M | -108.89M | -115.52M | -106.75M | -75.24M | -13.30M |
| Interest Expense | 209.00K | 565.00K | 1.01M | 972.00K | 3.43M | 634.00K |
| Other Income (Expense) | 5.20M | 5.85M | 5.05M | 1.39M | -34.62M | -1.05M |
| Pretax Income | -115.11M | -103.04M | -110.47M | -105.36M | -109.86M | -14.35M |
| Income Tax | 69.00K | 70.00K | 100.00K | -461.00K | -8.90M | 0 |
| Net Income | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M | -14.35M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 |
| EPS (Diluted) | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 |
| Shares Outstanding (Basic) | 136.78M | 110.24M | 92.03M | 90.85M | 49.69M | 15.49M |
| Shares Outstanding (Diluted) | 136.78M | 110.24M | 92.03M | 90.85M | 49.69M | 15.49M |
| EBITDA | -108.58M | -95.50M | -101.52M | -93.71M | -68.58M | -12.17M |
| Operating Margin | -4297.04% | -2401.59% | -2020.20% | -1857.49% | -1573.36% | -278.26% |
| Net Margin | -4113.68% | -2274.06% | -1933.65% | -1825.37% | -2111.25% | -300.27% |
This table shows 6 annual periods of Absci's income statement, from FY 2025 back to FY 2020, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ABSI's reporting calendar. What is a income statement?